RxDoctor Payments Data

Julia Parsons

Family · Sidney, NYNPI 1215286299

Payments from drug & device makers

$643in general payments, 2019–2025

Across 21 payments — averaging $30.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$274
  • AstraZeneca$59
  • Pfizer$54
  • AbbVie$52
  • Indivior Inc.$36
  • Novo Nordisk$35
  • plus $134 from 6 others

What the payments were for

  • Food & beverage$643100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$643 in reported general payments places this provider in the 65th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$30,330
Medicare patients
131
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$194,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$84,645
EliquisApixaban65$58,643
BiktarvyBictegrav/Emtricit/Tenofov Ala12$44,459
TrulicityDulaglutide39$37,894
JardianceEmpagliflozin19$29,566
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl169$25,841
Breo ElliptaFluticasone/Vilanterol37$24,151
Spiriva RespimatTiotropium Bromide25$19,542
XareltoRivaroxaban11$17,225
InvokanaCanagliflozin20$15,238
FarxigaDapagliflozin Propanediol17$13,660
Tresiba Flextouch U-100Insulin Degludec25$13,093
Albuterol Sulfate HfaAlbuterol Sulfate227$8,822
SymbicortBudesonide/Formoterol Fumarate29$8,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$194,932173 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$33$113,606116 claims
PfizerEliquis$54$58,64365 claims
Lilly USA, LLCTrulicity$18$37,89439 claims
AstraZenecaFarxiga, Symbicort$59$22,22046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,883 family providers in New York.

Other family in Sidney

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →